Introduction {#S5}
============

Transient Epileptic Amnesia (TEA) is a form of adult onset temporal lobe epilepsy characterised by repeated transient episodes of memory impairment, which occur in the absence of other significant cognitive disruption. For the majority, this ictal amnesia is accompanied by some degree of persistent, interictal memory difficulty, usually autobiographical amnesia \[[@R1],[@R2]\], accelerated long term-forgetting \[[@R3]--[@R6]\] or topographical amnesia \[[@R7]\]. i.e. memory for routes and places. Although cases of TEA have been described since 1889 \[[@R8]\], the recognition of TEA as a distinctive subtype of TLE is relatively recent, with specific diagnostic criteria outlined in 1998 \[[@R9]\]. As a result, while several studies characterise features at presentation, there is little information regarding long term prognosis. Evidence from shorter term follow up, however, suggests that while interictal memory problems may persist, the cognitive profile remains stable once the seizures are successfully treated with anticonvulsant medication \[[@R10]--[@R12]\]. Whether this is true over the longer term is currently unclear.

Longitudinal studies of other forms of TLE suggest that while memory performance of such patients may be below age-matched peers, declines over time do not generally exceed rates seen in normal ageing \[[@R13]\] and are therefore not usually suggestive of a neurodegenerative process. Prognosis in this group has been related to the type of seizure (with greater risk occurring if the patient's epilepsy includes generalised seizures), the number of uncontrolled seizures, and the age of onset (earlier onset predicting a poorer outcome)\[[@R14]\]. This bodes well for people with TEA, as the majority do not experience generalised seizures, respond well to medication, and do not develop the condition until their midlife \[[@R7]\].

Nevertheless, TEA was recently described in a woman who developed Alzheimer's Disease (AD) 16 years later\[[@R15]\]. While potentially coincidental, the authors suggest that TEA may have been the first sign of this disease. Similarly, cases diagnosed with Epileptic Amnesic Syndrome (EAS) have developed AD \[[@R16]\]. 'EAS' denotes a syndrome closely resembling TEA but also encompassing patients with interictal memory disturbance in the context of subtle, non-amnesic, temporal lobe seizures. Amnesic seizures have been also noted, occasionally as a presenting feature, among patients with Mild Cognitive Impairment and early AD\[[@R17],[@R18]\]. While this is usually in the context of other seizure types, taken together, the emergence of such cases has served as a warning that TEA and EAS may not be as benign as originally thought.

The current study presents the clinical and cognitive outcome of patients with TEA first reported in 1998 who have been long-term participants in the TIME project (The Impairment of Memory in Epilepsy - <http://projects.exeter.ac.uk/time/>). From the original series of 10 participants\[[@R9]\], we present follow-up information on 9 individuals over a 20-year period, with 3 detailed case reports. These unique long-term data provide insights into the prognosis of TEA.

Method {#S6}
======

Participants {#S7}
------------

All participants took part in the 1998 published study\[[@R9]\] of TEA (T1). The diagnosis of TEA was established via clinical assessment by an experienced behavioural neurologist (AZ). In all cases, the repeated amnesic episodes had been witnessed by the participant's spouse. Evidence of epilepsy was confirmed through any combination of epileptiform abnormalities on EEG, reports of concurrent classically epileptic features (e.g. olfactory hallucinations, automatisms) and /or a positive treatment response to anticonvulsant therapy.

All available participants from the 1998 study were then recruited to the TIME study as part of the 2007 series (T2) \[[@R7]\], and invited to a third follow up 10 years later (T3).

The study was approved by the Multicentre Research Ethics Committee, United Kingdom (MREC 03/10/77). All participants gave written, informed consent.

Measures {#S8}
--------

Updated medical information regarding memory complaints, ongoing seizures and other significant medical events was collected either via clinical interview directly with the participant or through their General Practitioner. Where possible, participants also underwent neuropsychological re-assessment. This included administration of the following measures: general intellectual functioning: National Adult Reading Test (NART) \[[@R19]\] was used at T1 to estimate IQ. At T2 and T3, the 4-subtest version of the Wechsler Abbreviated Scale of Intelligence (WASI)\[[@R20]\] was used.Visuospatial/visuoconstructional skills: Rey Complex Figure Test (RCFT)\[[@R21]\] -- copy trial.Visual delayed recall: 30 minute free recall of the RCFT.Verbal immediate and delayed recall: Story 1 (Anna Thompson) from the Logical Memory (LM) subtest of the Wechsler Memory Scale (WMS-R version at T1 and WMS-III version at T2)\[[@R22]\].Recognition memory: Warrington Recognition Memory Test (RMT)\[[@R23]\] - Words and Faces subtestsSemantic memory: Graded Naming Test (GNT)\[[@R24],[@R25]\] at T2 and T3Executive function: verbal fluency \[[@R26],[@R27]\]and Wisconsin Card Sorting Test -- 64 Card Version\[[@R28]\] at T2 and T3.

Data include either age-corrected percentile ranks, or raw scores if these were not available, to interpret performance over time. Clinically significant impairment was defined as test performance that was less than or equal to the 10^th^ percentile. Performance was considered stable if the percentile rank remained within a similar range (e.g. if scores remained within the normal range of 25-75^th^ percentile, above 75^th^ percentile, or below average range 10-25^th^ percentile; or if scores were in overlapping percentile ranges, such as "75-95" and then 75^th^). Where test norms did not adjust for differences in age over time, stability was assumed if raw scores remained relatively unchanged (i.e. allowing for minor decrements that may be expected from measurement error).

Results {#S9}
=======

[Table 1](#T1){ref-type="table"} summarises each participant's clinical presentation, [Table 2](#T2){ref-type="table"} the clinical outcomes over the 10 to 20-year period, and [Table 3](#T3){ref-type="table"} the neuropsychological test performance. [Figure 1](#F1){ref-type="fig"} provides a summary of participant numbers at each time point.

Participant characteristics at presentation (T1) {#S10}
------------------------------------------------

At T1, participants comprised 9 males and 1 female. Age of onset of TEA ranged from 49 to 78 years, with a mean age of 63 years. In half the cases, amnesic seizures lasted under an hour, but in two cases extended beyond a day (cases 3 and 5). Frequency of these seizures was commonly estimated at once a month (cases 1,6,7,8,9). All participants had experienced at least one amnesic episode on waking, with attacks exclusively on waking in two cases (cases 1 and 2). In three cases (cases 4, 5 and 7), attacks were purely amnesic, without additional epileptic features. The remaining 7 participants had other features at the time of at least some of their amnesic seizures, including olfactory hallucinations (cases 1 and 3), automatisms (cases 6,8,9,10), or déjà vu (case 6). Seven participants had additional simple partial, complex partial or tonic clonic seizures. EEG abnormalities were present in 8 cases: 4 which were epileptiform and 4 non-specific. Seizures ceased on initial treatment in 8 of the 10 cases.

All participants presented with memory complaints, most commonly retrograde amnesia (Cases 1,2,3,8,9,10), followed by accelerated forgetting of new information (Cases 1,4,10). Neuropsychological assessment at T1 indicated average to above average intellectual ability ([Table 3a](#T3){ref-type="table"} and [3b](#T4){ref-type="table"}). Overall, as a group, performance on standard memory measures was normal, although some impairments on tests were observed at an individual level \[[@R9]\]. In particular, Case 2 showed poor verbal and visual delayed recall memory; Case 7 showed poor verbal recall and impoverished face recognition (all scoring below the 10^th^ percentile).

Clinical and cognitive outcomes 10 years later (T2) {#S11}
---------------------------------------------------

Information regarding 9 participants was available at the first 10-year follow-up. Of these, one participant (Case 3) had died, following a ruptured aortic aneurysm. Preceding his death there were no documented concerns regarding his cognition, beyond the original reports of marked autobiographical amnesia. A neuropsychological assessment completed 9 months prior to death showed no evidence of cognitive decline\[[@R29]\]. The remaining eight individuals underwent a full re-assessment \[[@R7]\]. Seven participants continued to have good seizure control on anti-convulsant medication (with ≤ 1 further episode per participant over the 10-year period). The remaining participant (Case 6), who had abandoned treatment after 7 weeks, also reported an absence of seizures during this period.

Self-reported cognitive outcomes varied from no persisting memory difficulty (Cases 6 & 7) to either stable memory deficits (Cases 4,8,10) or reports of worsening memory (Cases 1,2,9). On objective neuropsychological assessment, however, when accounting for age, performance typically remained steady or showed minor improvements (i.e. percentile rankings remained within a similar range or increased; see [Table 3a](#T3){ref-type="table"} and [3b](#T4){ref-type="table"}). An exception to this was in face recognition, where clinically significant impairments were observed now in 3 cases (2,7 and 8). Some additional decline was also evident for immediate recall of a story for Case 2, however, on other tasks he remained stable or slightly improved ([Table 3a](#T3){ref-type="table"}).

Clinical and cognitive outcomes 20 years later (T3) {#S12}
---------------------------------------------------

At the second 10-year follow-up, 3 additional participants had now died (cases 6,7,9, see [Figure 1](#F1){ref-type="fig"}). Causes of death were pneumonia, mesothelomia, and cardiac failure. There was no indication of a dementia or significant cognitive concerns in these cases beyond the deficits initially recorded at the time of diagnosis. In each case, age at death exceeded current life expectancy estimates for males (79.35 years)\[[@R30]\]. Of the remaining 5 participants, 3 were now in their 80s. Four participants had continued their treatment on anticonvulsant medication, with no further reports of seizures in two participants. An additional participant was also reportedly seizure free, despite having ceased taking anticonvulsants in 2005. In the remaining 2 participants (cases 4 and 10), some re-emergence of episodes had occurred. One participant (case 8) suffered multiple strokes and was diagnosed with vascular dementia, with associated cognitive declines and did not participate further in the study.

Assessment of subjective memory complaints in the remaining 4 cases revealed either ongoing but stable impairments (cases 1 and 2) or reported worsening of memory (cases 4 and 10). All 4 participants were living at home independently. Three participants (cases 1, 4, 10) underwent a further neuropsychological re-assessment. We summarise the key features and findings in these cases in the following detailed descriptions.

Case 1 -- 83 year old male, retired engineer {#S13}
============================================

Case 1 presented in 1995 aged 63 with a 3-year history of monthly episodes of transient amnesia lasting for around one hour each, mostly on waking, involving a retrograde amnesia of up to 30 years. He sometimes complained of a strange smell or taste at attack onset. MRI and EEG were normal. The attacks ceased when he was treated with carbamazepine. He changed to lamotrigine because of drowsiness. Initial cognitive assessment estimated his intellectual functioning to be within the average range, with commensurate performance on standard memory tests.

At follow-up in 2005, only one additional attack was reported, following dose reduction. On returning to his previous dose, he remained attack-free. He underwent a research brain MRI, with no abnormalities reported ([Figure 2A](#F2){ref-type="fig"}). Despite this, at review he complained of worsening memory difficulties involving accelerated forgetting of new information and patchy loss of salient autobiographical memories. Neuropsychological assessment at T2, however, indicated a stable profile of skills -- with small increases, rather than decreases, in scores of visual and verbal delayed recall. General cognitive ability was measured within the high average range and he performed well on measures of executive function.

Medical review in 2015 indicated that he was well, with no further episodes of amnesia on continuing anticonvulsant treatment. He was living alone, independently. On self-report, he indicated ongoing difficulty with forgetting new information. Neuropsychological review at T3 revealed continued stability in general knowledge and problem solving, but some reduction in visual skills, as seen in both his drawing and recall of the complex figure. His recognition of faces, which are viewed briefly, was also reduced from T2, now falling within the clinically impaired range (below the 10^th^ percentile). Although some decline in encoding verbal information (a story) was evident, his delayed recall remained very similar to that shown 20 years earlier. Semantic memory remained stable and he continued to perform well on speeded word generation tasks.

Case 4 -- 87 year old female, previous almoner and housewife {#S14}
============================================================

Case 4 presented aged 67 with five episodes of transient amnesia over a 15-year period, with no other seizure features. Brain CT and wake EEG were normal, but a sleep study revealed unequivocal left temporal epileptiform abnormalities. She was treated with carbamazepine, with one further episode after which dosage was adjusted. Cognitive assessment suggested above average intellectual functioning, with performance on standard memory tests at least within the average range for her age.

At her clinical follow up in 2005, no further seizures had occurred. She underwent a research brain MRI, with no abnormalities reported ([Figure 2B](#F2){ref-type="fig"}). Despite this, she complained of ongoing difficulty with retaining new information, which she felt faded over the course of a few hours. Her husband, however, had not observed any significant memory problem. Neuropsychological assessment at T2 showed no evidence of decline in any cognitive domain, with improved scores on verbal delayed recall (over a 30-minute period), despite her increasing age.

She had two possible minor amnesic seizures over the next 10 years. Following an increase in medication (CBZ), no further episodes were recorded. At reassessment in August 2015, she complained of worsening memory, but was living alone independently.

Neuropsychological performance remained generally stable over the 20-year period for visuospatial skills, initial verbal encoding and recognition of faces. Performance on a novel problem solving task remained at the 99^th^ percentile. Declines, however, were evident in delayed recall of visual and verbal information when comparing performance from T2 to T3, and she now showed impaired recognition memory for words (below the 10^th^ percentile). Performance on many tasks, however, remained within the normal range for her age.

Case 10 -- 77 year old male, retired lecturer {#S15}
=============================================

Case 10 presented at age 57 with a 5-year history of numerous episodes of anterograde amnesia, commonly occurred on waking from naps, together with other seizures including three witnessed tonic-clonic convulsions. Prior to these episodes, his medical history included one fit at age 2 and another when aged 23. Brain MRI in 1995 showed focal atrophy of the right hippocampus, which was unchanged on serial imaging in 2000 and 2003. Treatment with carbamazepine abolished both the episodes of amnesia and overt seizures. His cognitive assessment suggested above average intellectual functioning, with performance on memory measures generally within the average range for his age. Although his initial verbal recall of a story was adequate, his retention of this information appeared somewhat reduced.

At his clinical follow up in 2005, no additional attacks were reported although he continued to complain of memory difficulties both in recalling events from his distant past, as well as learning new information. Results of his neuropsychological assessment at T2, however, indicated little change over the 10-year period, with slight improvements in his delayed recall of information. Recognition memory for words was stable, with some lowering in recognition of faces. His research brain MRI conducted at this time did not reveal any additional abnormalities ([Figure 2C](#F2){ref-type="fig"}).

In 2008, he had an episode of encephalopathy associated with hyponatraemia. This improved with reduction in his dose of carbamazepine, but he was left with continuing fatigue, concentration difficulty and emotional lability. In July 2014, he reported experiencing 3-4 "vacant episodes" per year. Brain MRI was repeated, noting again the original hippocampal asymmetry, evidence of small vessel disease, and now moderate global atrophy. In December 2014, he had an episode of delirium and an exacerbation of his seizures following introduction of leveteracitam. At the time of his 2015 neuropsychological review, the last seizure had been 2 weeks prior. He reported difficulties concentrating and recognising faces from recent past. This included neighbours from the last 5 years and one of his grandchildren.

Neuropsychological assessment at T3 suggested little or no change in general intellectual ability or problem solving. Encoding of verbal information had dropped, although retention of information learned after a 30 minute delay was good. Visuoconstructional skills (drawing) were not impacted and recall of visual information, when adjusted for age, remained steady over the 20-year period (originally 46^th^percentile, then 62^nd^, then 54^th^). Consistent with the participant's self-reported difficulties, further decline in recognising faces was evident, with performance now within the clinically impaired range. Additional impairments arose in semantic memory and speeded thinking.

Telephone contact with the family 6 months later indicated seizures were now controlled. Although no objective assessment was conducted, reports from his wife suggested improvement in alertness and general cognition.

Discussion {#S16}
==========

The long-term outcome of a group of patients with TEA has not been reported previously, leaving the prognosis of this disorder uncertain. We describe longitudinal findings over 20 years in a group of patients first reported in 1998. Follow-up data were available for 9 out of these 10 participants. Results indicated that TEA had no major adverse impact on life expectancy. During the first 10-year period, the majority of patients remained seizure free, with little evidence of cognitive change, and in some cases, minor improvements on neuropsychological testing. Over the following 10 years, control of seizures remained generally good. One participant developed vascular dementia. Significant cognitive impairments were also observed in a second patient, associated with seizure recurrence and complications of therapy. In the remaining participants, while some declines occurred, considerable stability was observed for many tasks over the 20-year period. Where declines were found, the cognitive domain most often affected was visual recognition memory. Importantly, and in contrast to the previous case report by Cretin and colleagues\[[@R15]\], the results of this series do not suggest a substantially increased risk of AD among patients with TEA.

The initial stability observed for the majority of participants within this series is consistent with existing reports within the literature that have followed up patients at shorter time intervals (e.g. 9 months to 2 years). In these studies, anti-convulsants were successful in abolishing seizures, with cognitive performance either remaining stable \[[@R12]\] or showing some minor improvements on memory scores \[[@R10],[@R31]\]. Likewise, in the current series, test performance tended to be unchanged or slightly improved at the first 10-year follow up, coinciding with good seizure control. Interestingly, neuropsychological test results did not always coincide with an individual's subjective reports of memory, where worsening was reported at times. This discrepancy may in part reflect increasing awareness of memory gaps over time (e.g. through conversations with others, becoming aware of additional lost autobiographical memories), as well as the difficulty in capturing certain types of memory deficits with standardised neuropsychological tests. Regardless, the results at 10 years suggest that even in the context of increasing memory concerns for some patients, changes in broader memory skills were minimal. Where reductions were observed, this did not extend across multiple measures of memory (for example, Case 7 showed some lowering in scores for recognition of words and faces, but some improvements to verbal memory, with somewhat steady age-adjusted visual recall performance), and generally did not involve a striking change in score over a 10-year period.

Greater variability in cognitive performance was observed over the second 10-year period. One participant was now diagnosed with vascular dementia. This appears consistent with estimated base rates of dementia prevalence within this age bracket\[[@R32]\]. No participants, however, were diagnosed with AD, despite several participants living into their 80s. In the 4 deceased participants, there were no reports of significant cognitive decline prior to death. In the remaining participants who underwent neuropsychological assessment at T3, general cognitive ability remained above average, although some declines in memory were observed. The nature and degree of these declines, however, varied. The individual who showed the greatest cognitive impairment (Case 10), experienced changes within the context of re-emerging seizures and significant fatigue, with an overall neuropsychological profile that was not typical of AD\[[@R33]\] (given his visuoconstructional skills and problem solving remained stable and within the normal range and his ability to retrieve learned information after a delay was not indicative of rapid forgetting). In the other two cases assessed at 20 years, both continued to perform highly on certain neuropsychological tests for their age and were living alone independently, indicating a maintained functional ability in everyday life that would not support a dementia diagnosis.

Interestingly, the most consistent impairment on neuropsychological testing was on the Faces subtest of the Warrington Recognition Memory Test. Over the course of the study, 5 of the 9 participants performed within the clinically impaired range, suggesting that visual recognition impairments are a common neuropsychological feature of TEA. This has been noted in previous case reports\[[@R34],[@R35]\] and is consistent with another recent study of TEA where significant impairments in picture recognition were found when using a challenging visual task \[[@R36]\]. Performance on the Warrington Faces has been found to correlate with right hippocampal volumes in TEA, with significant, although subtle, reductions in volume compared with matched healthy controls \[[@R37]\]. Under-functioning in adjacent regions of the brain has also been reported in a study of autobiographical memory, where TEA participants showed reduced activation in the right parahippocampal gyrus relative to controls \[[@R38]\]. Declines over time on the Warrington Faces task may therefore reflect increasing structural or functional changes within key right temporal brain regions, which should be explored in future studies.

Thus, while the case description by Cretin and colleagues raised the possibility that TEA was the first sign of dementia, this does not seem to be the case in our series. It is noteworthy that the woman described had a family history of Alzheimer's Disease, given her mother's diagnosis at age 70, which may have been an important predisposing factor in this case\[[@R15]\]. Although no participant in our series appeared to develop AD within the 20-year timeframe, variability in cognitive outcome was still observed and persistent memory complaints were common. We note that the average intelligence of our participants was high, which may have served as a protective factor against developing dementia \[[@R39]\]. Future longitudinal studies including individuals with lower IQ will be important in determining any potential differences in outcome.

Beyond the cognitive results, the current study also provides information regarding seizure outcomes in relation to the long term use of anticonvulsant medication in TEA. Consistent with short-term follow up reports in TEA, few if any seizures were reported over the 20-year period for those remaining on medication, with the exception of Case 10 and Case 4, where adjustments were required after 10 years. Two participants (Cases 2 and 6) discontinued treatment with anticonvulsants -- either initially or after 10 years - and remained seizure free. These results suggest that, as in other adult-onset focal epilepsies, some patients with TEA benefit from continuing anticonvulsant treatment while others can achieve seizure freedom following treatment withdrawal.

Our study has some limitations. The evaluation of neuropsychological outcomes involved interpreting age-corrected values of standard measures where possible. However, the norms used were cross-sectional rather than longitudinal and thus only provided a crude measure to evaluate normal change over time. In addition, standard measures are limited in their ability to assess autobiographical memory deficits and forgetting that occurs beyond a half hour delay. We aim to address these limitations in a subsequent prognosis study.

The sample size is small. The demographic and clinical characteristics, however, mirror those reported in larger TEA groups, regarding male predominance, age of onset, seizure frequency, initial treatment response, and average to above intellectual functioning \[[@R7],[@R31]\]. Thus while small, the group studied appears representative. Moreover we were able to follow up 9 of the 10 original cases, reducing selection bias in reporting of outcomes. While our data are reassuring with respect to the risk of dementia among patients presenting with classical features of TEA, we are unable to exclude Alzheimer pathology via either pathological confirmation at autopsy or biomarkers such as cerebrospinal fluid. Such studies are clearly needed. In the interim, this study provides the most comprehensive information currently available on long-term outcome in TEA.

Conclusion {#S17}
==========

We conclude that while TEA can be a prelude to AD this appears to be rare. Based on a detailed, very long-term follow-up of cases, treated TEA has a relatively benign outcome, with good long-term seizure control in the majority of patients, substantial stability of cognitive performance and no evidence, from this small group study, of an elevated risk of dementia.
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###### Highlights

-   Nine patients with TEA were followed up over a 20-year period

-   Subjective complaints of memory difficulty were common at all time points

-   Memory performance showed stability at 10 years, with some declines at 20 years

-   At 20 years, only one participant was diagnosed with (vascular) dementia

-   Cognitive decline in another case linked to recurrent seizures/drug side-effects

![Flow diagram of participant follow-up over the three time periods (T1, T2 and T3). Nk = not known. Only one participant is diagnosed with (vascular) dementia throughout the period of the study.](emss-79762-f001){#F1}

![T1 coronal MR brain images for A) Case 1 (age 73), B) Case 4 (age 76), and C) Case 10 (age 66). All images were acquired at the first 10-year follow-up period (T2). Note the left hemisphere is shown on the left. Case 10 had moderate right hippocampal atrophy.](emss-79762-f002){#F2}

###### Clinical characteristics of TEA participants

  ID   Sex   Age at onset   Duration of attacks   Approx Frequency of attacks   Seizure features                  Other epilepsy   EEG                          Initial treatment response
  ---- ----- -------------- --------------------- ----------------------------- --------------------------------- ---------------- ---------------------------- ----------------------------
  1    M     60             30-60 mins            Monthly                       All on waking, Olf hall           sps              Normal                       Yes - LAM
  2    M     49             15-30 mins            Twice/month                   All on waking, Pure amnesia       sps              epileptic                    Yes - CBZ
  3    M     68             Hrs-days              No pattern                    On waking, Olf hall               sps, cps         epileptic                    Yes -SVP
  4    F     52             2-24 hrs              Twice/ yr                     On waking, Pure amnesia           none             epileptic                    Yes - LAM
  5    M     78             Hrs-days              Twice/ yr                     On waking                         none             epileptic                    Equivocal reduction -- CBZ
  6    M     69             15-30 mins            Monthly                       On waking, automatisms, déjà vu   sps              Non-specific abnormalities   Not treated
  7    M     73             1-3 hrs               Monthly                       On waking, Pure amnesia           none             Non-specific abnormalities   Yes - Phen
  8    M     60             2-24 hrs              Monthly                       On waking, automatisms            cps, tcl (1)     Normal                       Yes - SVP
  9    M     69             20-60 mins            Monthly                       On waking, automatisms            cps              Some abnormalities           Yes - CBZ
  10   M     52             15-30 mins            Twice/wk                      On waking, automatisms            cps, tcl (3)     Some abnormalities           Yes - CBZ

CBZ = carbamazepine; LAM = lamotrigine; SVP = sodium valproate; Phen = phenytoin, sps = simple partial seizures; cps = complex partial seizures; tcl = tonic-clonic seizures; Olf hall = olfactory hallucination

###### Clinical review -- Seizure history, medication and subjective cognitive outcomes

  ID   Current Status   Current Age   No. of amnesic seizures   Treatment history   Dementia Diagnosis   Subjective cognitive complaints                                                                Additional clinical notes                                                                                                                                                                                                                                          
  ---- ---------------- ------------- ------------------------- ------------------- -------------------- ---------------------------------------------------------------------------------------------- --------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1    Living           83            50                        1                   0                    Initial change from CBZ to LAM. No change from 1996                                            No                          At T1, ALF and patchy RA extending 30 years. At T2, reported ongoing memory concerns since onset, with more pronounced forgetting of new information. At T3, reported similar ongoing concern of fast forgetting of new information.   No significant concerns regarding cognition by medical team
  2    Living           71            10                        0                   0                    Treated on CBZ for 10 years; phased out in 2005 due to associated fatigue                      No                          At T1, RA extending 30 years. At T2, reports of ongoing concerns, with RA now extending 40 years. At T3, stable memory complains                                                                                                       No significant concerns regarding cognition by medical team. Participant reports "life has returned to near normal apart from the loss of part of my memory"
  3    Deceased         74 at death   5                         nk (\>1)            \-                   Treated with SVP for 2 years; topirmate added in 1997 when seizures recurred                   No                          At T1, RA extending 30 years. Died in 1999, 5 years prior to T2 follow up.                                                                                                                                                             Cause of death was ruptured aortic aneurysm. Neuropsychological assessment 9 months prior to death showed average performances across tasks, with no evidence of decline.
  4    Living           87            5                         1                   ?2                   2009 one increase to dosage of LAM                                                             No                          At T1, ALF. No concerns of RA, although remote memories reported to be "less vivid". At T2, ongoing memory concerns were reported. At T3, concerns of worsening memory                                                                 No significant concerns regarding cognition by medical team
  5    unknown          unknown                                                                          Treated with CBZ. Effectiveness unknown. Lost to follow up                                     No                          At T1, patchy amnesia for recent events.                                                                                                                                                                                               unknown
  6    Deceased         89 at death   15                        0                   0                    Treated with CBZ for 7 weeks but discontinued due to a rash. No further treatment              No                          At T1, difficulties with day to day memory. At T2, reported no persistent memory difficulties                                                                                                                                          Cognitive impairments (poor memory) but no indication of dementia. Assessed by medical team 3 months prior to death. Dementia screening concluded "no major concerns about cognition". Cause of death was pneumonia.
  7    Deceased         84 at death   6                         0                   \-                   Stable on Phenytoin                                                                            No                          At T1, minor forgetfulness. At T2, reported no persisting memory difficulties                                                                                                                                                          No cognitive difficulties noted and independent in activities of daily living on medical review 4 months prior to death. Cause of death was mesothelomia
  8    Living           81            6                         0                   nk                   Stable on SVP                                                                                  Yes - VD                    At T1, patchy RA extending 30 years, and poor day-to-day memory. At T2, reports of ongoing memory concerns since onset. Between T2 and T3, increased cognitive difficulty associated with CVAs.                                        Impaired cognition associated with Vascular Dementia (diagnosed in 2013). Multiple CVAs, resulting in cognitive impairments.
  9    Deceased         83 at death   5                         ?1                  \-                   Stable on CBZ                                                                                  No                          At T1 patchy RA extending 25 years. At T2 reported ongoing memory concerns since onset, with additional fading recall of recent events                                                                                                 Died awaiting a second aortic valve replacement. No record of significant concerns regarding cognition by medical team
  10   Living           77            ≥20                       0                   ≥ 10                 Stable on CBZ until 2008 then multiple reductions in dosage required; 2014 changed AED (LEV)   No                          At T1, ALF and patchy RA extending 10 years. At T2, reports of ongoing memory concerns since onset. Additional cognitive difficulty from 2008 onwards                                                                                  Patient and family report significant difficulties with fatigue, attention and concentration

CBZ = carbamazepine; LAM = lamotrigine; SVP = sodium valproate; LEV = leveteracitam; ALF = accelerated long-term forgetting; RA = retrograde amnesia; VD = Vascular Dementia; nk = not known

###### Neuropsychological test performance for participants assessed over T1 and T2 only (Score or percentile)

                                         Case 2                                  Case 6                                     Case 7   Case 8   Case 9                                                                                                                                         
  -------------------------------------- --------------------------------------- ------------------------------------------ -------- -------- ------------------------------------------ ----------------------------------------- ------- ------------------------------------------ ------ -------
  **IQ/ Estimated IQ**                   110                                     113                                        114      132      105                                        100                                       116     120                                        120    129
  **RCFT -- copy (/36)**                 32                                      32                                         33       35       34                                         34                                        33      34                                         35     35
  **LM (Story 1) -- Immediate (/25)**    9                                       6                                          16       16       7.5                                        12                                        14.5    14                                         15     18
  **LM (Story 1) -- Delay (/25)**        **5[\*](#TFN3){ref-type="table-fn"}**   **4[\*](#TFN3){ref-type="table-fn"}**      14       15       **1.5[\*](#TFN3){ref-type="table-fn"}**    **3[\*](#TFN3){ref-type="table-fn"}**     13      14                                         11     14
  **RCFT -- 30 minute delay (%ile)**     **3[\*](#TFN3){ref-type="table-fn"}**   27                                         54       97       54                                         46                                        66      46                                         93     82
  **RMT -- Words (%ile)**                25                                      50                                         75-95    75       50-75                                      25                                        75      \>95                                       95     95
  **RMT -- Faces (%ile)**                25-50                                   **\<5[\*](#TFN3){ref-type="table-fn"}**    50-75    50       **5-10[\*](#TFN3){ref-type="table-fn"}**   **\<5[\*](#TFN3){ref-type="table-fn"}**   25-50   **5-10[\*](#TFN3){ref-type="table-fn"}**   \>95   \>95
  **GNT (/30)**                          \-                                      **11[\*](#TFN3){ref-type="table-fn"}**     \-       22       \-                                         20                                        21      23                                         \-     23
  **Letter fluency -- FAS (%ile)**       \-                                      **2[\*](#TFN3){ref-type="table-fn"}**      \-       11                                                  **3-5[\*](#TFN3){ref-type="table-fn"}**           29-40                                             60-71
  **Category fluency (%ile)**            \-                                      **\<10[\*](#TFN3){ref-type="table-fn"}**   \-       50-75    \-                                         90                                        75-90   50-75                                      \-     \>90
  **WCST perseverative errors (%ile)**   \-                                      \-                                         \-       \>99     \-                                         39                                                \>99                                       \-     \>99

clinically impaired scores of ≤ 10% ile or -1.3 SDs below control mean; Norms used: RCFT \[[@R21]\]; LM \[[@R7]\]; RMT \[[@R23]\]; GNT \[[@R25]\]; Letter fluency \[[@R27]\], Category fluency \[[@R26]\]; WCST \[[@R28]\]. For RCFT -- copy, all scores reflect performances ≥ 16^th^%ile unless marked otherwise. For RMT, age-adjusted percentiles only include 40-54 years and 55 years and above.

###### Neuropsychological test performance for participants assessed over T1-T3 (Score or percentile)

                                         Case 1   Case 4   Case 10                                                                                                           
  -------------------------------------- -------- -------- ----------------------------------------- ------- ------- --------------------------------------- ------- ------- -----------------------------------------
  **IQ/ Estimated IQ**                   110      117      112                                       123     138     129                                     120     116     112
  **RCFT -- copy (/36)**                 34       31       **21[\*](#TFN4){ref-type="table-fn"}**    36      36      36                                      36      36      33
  **LM (Story 1) -- Immediate (/25)**    16       17       11                                        16      18      16                                      16      14      7
  **LM (story 1) -- Delay (/25)**        12       15       11                                        10      15      8                                       9.5     12      6
  **RCFT -- 30 min delay (%ile)**        50       69       42                                        88      84      31                                      46      62      54
  **RMT -- Words (%ile)**                \>95     75-95    75-95                                     75-95   75-95   **5[\*](#TFN4){ref-type="table-fn"}**   50-75   50-75   25-50
  **RMT -- Faces (%ile)**                50       50-75    **\<5[\*](#TFN4){ref-type="table-fn"}**   75      75-95   75                                      75-95   25-50   **\<5[\*](#TFN4){ref-type="table-fn"}**
  **GNT (/30)**                          \-       22       22                                        \-      25      21                                      \-      19      **15[\*](#TFN4){ref-type="table-fn"}**
  **Letter fluency (%ile)**                       82-89    60-71                                             82-89   29-40                                           19-28   2
  **Category fluency (%ile)**                     \>90     \>90                                              \>90    50-75                                           25      \<10
  **WCST perseverative errors (%ile)**   \-       90       16                                        \-      \>99    \>99                                    \-      21      63

clinically impaired scores of ≤ 10% ile or -1.3 SDs below control mean; Norms used: RCFT \[[@R21]\]; LM \[[@R7]\]; RMT \[[@R23]\]; GNT \[[@R25]\]; Letter fluency \[[@R27]\], Category fluency \[[@R26]\]; WCST \[[@R28]\]. For RCFT -- copy, all scores reflect performances ≥ 16^th^%ile unless marked otherwise. For RMT, age-adjusted percentiles only include 40-54 years and 55 years and above.
